Loading patent…
AssigneesThe Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy, Imperial Innovations Limited, Duke University
InventorsPeter HUMPHRIES, Marian HUMPHRIES, Matthew CAMPBELL, Anna-Sophia KIANG, Daniel STAMER, Darryl Ray OVERBY, Chi Shing Lawrence TAM
Estimating the term…
The present invention is directed to an RNAi-inducing agent capable of reducing and/or inhibiting the expression of proteins associated with the tight junction complex joining Schlemm's canal endothelial cells (SCEC) in the eye of a subject for use in the prevention and/or treatment of glaucoma. Specifically, the RNAi-inducing agent is capable of reducing and/or inhibiting the expression of proteins expressed in the tight junction complex or supporting the tight junction complex joining Schlemm's canal endothelial cells (SCEC) in the eye of a subject for use in the prevention and/or treatment of glaucoma. Methods using this RNAi-inducing agent are also contemplated.
1-18. (canceled)
A method for the prevention or treatment of glaucoma in a subject comprising the step of administering an effective amount of an RNAi inducing agent capable of reducing the expression of one or more tight junction proteins expressed in the tight junction complex joining Schlemm's canal endothelial cells (SCEC) in an eye of the subject.
(canceled)
A method for the prevention and/or treatment of glaucoma in a subject comprising the step of administering an effective amount of an RNAi-inducing agent capable of reducing the expression of adherens junction proteins which support the tight junction complex joining Schlemm's canal endothelial cells (SCEC),
Dependencies are inferred from the claim text.